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A B S T R A C T
Purpose: The pre-ejection period-derived myocardial performance index measured from tissue Doppler
echocardiography (PEPa-derived MPI) was reported to be associated with left ventricular systolic and
diastolic function in atrial ﬁbrillation (AF). However, its relationship with cardiovascular outcomes in AF
has never been evaluated. This study sought to examine the ability of PEPa-derived MPI in predicting
adverse cardiovascular events in AF patients.
Methods: In 196 persistent AF patients, we performed comprehensive echocardiography with
measurement of PEPa-derived MPI using index beat method. The index beat was deﬁned as the beat
following the nearly equal preceding (RR1) and pre-preceding (RR2) intervals. The cycle length of index
beat and RR1 and RR2 must be >500 ms and the difference between RR1 and RR2 must be <60 ms.
Cardiovascular events were deﬁned as cardiovascular death, nonfatal stroke, and hospitalization for
heart failure.
Results: In the multivariate analysis, chronic heart failure and increased ratio of transmitral E-wave
velocity to early diastolic mitral annulus velocity (E/Ea) and PEPa-derived MPI (per 0.1 increase, hazard
ratio, 1.104; 95% conﬁdence interval, 1.032–1.182, p = 0.004) were associated with increased
cardiovascular events. The addition of PEPa-derived MPI to a Cox model containing chronic heart
failure, systolic blood pressure, age, diabetes, prior stroke, left ventricular ejection fraction, and E/Ea
provided an additional beneﬁt in prediction of adverse cardiovascular events (p = 0.015).
Conclusions: In AF patients, the PEPa-derived MPI was a useful predictor of adverse cardiovascular
events and could offer an additional prognostic beneﬁt over conventional clinical and echocardiographic
parameters.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Atrial ﬁbrillation (AF) is the most common form of cardiac
arrhythmia and its prevalence increases with age, reaching 8% in
those older than 80 years [1,2]. AF is associated with an increased
risk of stroke, heart failure, and all-cause mortality [3]. Thus, early
detection of left ventricular dysfunction in AF patients is important* Corresponding author at: Department of Internal Medicine, Kaohsiung
Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, 482, Shan-Ming
Rd., Hsiao-Kang Dist., 812 Kaohsiung, Taiwan. Tel.: +886 7 8036783x3441;
fax: +886 7 8063346.
E-mail address: cobeshm@seed.net.tw (H.-M. Su).
http://dx.doi.org/10.1016/j.jjcc.2014.07.014
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsin predicting which patients are at high risk of developing
cardiovascular (CV) events and in providing therapeutic interven-
tion to reduce the future incidence of CV events and their
accompanied medical and social costs. AF is frequently associated
with left ventricular diastolic dysfunction, resulting in a consider-
able risk of developing heart failure with preserved ejection fraction
[3–5]. Inherently, left ventricular ejection fraction (LVEF) is not
perfect in prediction of CV outcomes in patients with heart failure
with preserved ejection fraction. Thus, concurrent consideration of
left ventricular systolic and diastolic function may be important and
necessary in improving CV outcome prediction in AF patients [6–8].
Myocardial performance index (MPI), a proposed indicator of
combined ventricular systolic and diastolic function, is deﬁned as reserved.
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isovolumic relaxation time (IVRT) over the ejection time (ET) [9–
12]. This index has been demonstrated to be a powerful and
independent prognostic indicator in non-AF patients [9,13–15].
IVCT was measured from the end of left ventricular diastolic
activity to the onset of left ventricular systolic activity. Because of a
loss of mechanical atrial function, the end of left ventricular
diastolic activity cannot be determined in patients with AF and
thus IVCT cannot be obtained in AF patients. In contrast, although
IVCT cannot be measured in patients with AF, pre-ejection period
(PEP) can be easily obtained in AF patients. The PEP has been
reported to correlate well with left ventricular systolic function
[16]. Therefore, using tissue Doppler echocardiography, we can
measure PEPa, deﬁned as the interval measured from the onset of
QRS to the onset of the systolic mitral annular velocity pattern, ETa,
deﬁned as the interval measured from the onset to the end of
systolic mitral annular velocity pattern, and IVRTa, deﬁned as the
interval measured from the end of systolic mitral annular velocity
pattern to the onset of diastolic mitral annular velocity pattern on
the same cardiac cycle. Recently, we have demonstrated that the
PEPa-derived MPI, deﬁned as the ratio of PEPa + IVRTa to ETa, was
signiﬁcantly associated with echocardiographic left ventricular
systolic and diastolic function in AF patients [17]. Because the
PEPa-derived MPI can concurrently reﬂect left ventricular systolic
and diastolic function, it has a potential to become a useful
parameter in prediction of adverse CV events in AF patients.
However, the prognostic value of PEPa-derived MPI in AF patients
has never been evaluated. Accordingly, the aim of the present
study was to examine the ability of PEPa-derived MPI in prediction
of CV outcomes in patients with AF. Besides, we also sought
whether PEPa-derived MPI could offer an additional prognostic
beneﬁt over conventional clinical and echocardiographic param-
eters in these patients.
Methods
Study patients
This observational cohort study prospectively and consecutive-
ly included patients with persistent AF referred for echocardio-
graphic examinations at Kaohsiung Municipal Hsiao-Kang Hospital
from April 2010 to June 2012. Persistent AF was deﬁned as AF
lasting for at least 7 days, which was conﬁrmed by 12-lead
electrocardiography (ECG), 24-h Holter ECG or ECG recording
during echocardiographic examination. Patients with severe mitral
stenosis (n = 2), severe mitral regurgitation (n = 5), moderate and
severe aortic stenosis or regurgitation (n = 4) and inadequate
echocardiographic visualization (n = 8) were excluded. Besides,
four patients who had no beat fulﬁlled the requirements of index
beat in the stored cardiac cycles were also excluded. Finally, 196
persistent AF patients were included in this study. The study
protocol was approved by our Institutional Review Board and
enrolled patients gave written, informed consent.
Echocardiographic evaluation
The echocardiographic examination was performed by one
experienced cardiologist with a VIVID 7 (General Electric Medical
Systems, Horten, Norway), with the participant respiring quietly in
the left decubitus position. The cardiologist was blind to the other
data. Two-dimensional and two-dimensionally guided M-mode
images were recorded from the standardized views. The Doppler
sample volume was placed at the tips of the mitral leaﬂets to
obtain the left ventricular inﬂow waveforms from the apical four-
chamber view. All sample volumes were positioned with
ultrasonic beam alignment to ﬂow. Pulsed tissue Doppler imagingwas obtained with the sample volume placed at the lateral and
septal corners of the mitral annulus from the apical four-chamber
view. The wall ﬁlter settings were adjusted to exclude high-
frequency signals and the gain was minimized. On the tissue
Doppler images, PEPa, IVRTa, ETa, early diastolic mitral annulus
velocity (Ea) and systolic mitral annulus velocity (Sa) were average
from septal and lateral ones. LVEF was measured using the
modiﬁed Simpson’s method. Left ventricular mass was calculated
using Devereux-modiﬁed method [18]. Left ventricular mass index
(LVMI) was calculated by dividing left ventricular mass by body
surface area. Left atrial volume was measured using the biplane
area-length method [19]. Left atrial volume index (LAVI) was
calculated by dividing left atrial volume by body surface area. The
raw ultrasonic data were recorded and analyzed ofﬂine using
EchoPAC software (EchoPAC version 08; GE-Vingmed Ultrasound
AS GE Medical Systems).
Left ventricular dimensions, LVEF, LAVI, LVMI, PEPa, IVRTa, Eta,
and PEPa-derived MPI were measured using the index beat method
[20–22]. Because their measurements were easy and rapid, the
transmitral E-wave velocity (E), E-wave deceleration time, Ea and
Sa were obtained from ﬁve beats [4] and the data were averaged to
give the mean value for later analysis. If the cardiac cycle length
was too short to complete the diastolic process, this beat was
skipped. Thus, the selection of E, E-wave deceleration time, Ea, and
Sa was not always consecutive. In addition, heart rate was
determined from ﬁve consecutive beats.
Index beat selection
The index beat taken after the nearly equal preceding and pre-
preceding intervals was selected from the stored cardiac cycles (at
least 15 beats). The preceding and pre-preceding intervals of the
index beat must be >500 ms [23], and the difference between
them must be <60 ms [22]. The cardiac cycle of the index beat was
also >500 m [23]. If patients had no beat that fulﬁlled the
requirements of the index beat in the stored cardiac cycles,
we excluded such patients (n = 4). If several beats fulﬁlled the
requirements of the index beat in the stored cardiac cycles,
we chose the index beat of ﬁrst appearance to calculate the
echocardiographic data. Fig. 1 illustrates the measurement of PEPa,
ETa, IVRTa, and PEPa-derived MPI from index beat in a
representative patient.
Assessment of association between index beat and average methods
Fifty-one patients were randomly selected for evaluation of the
association between PEPa-derived MPI obtained from index beat
and average methods. The PEPa-derived MPI obtained from
average method was measured from 13 cardiac cycles and the
data were averaged to give the mean value for later analysis.
Collection of demographic, medical, and laboratory data
Demographic and medical data including age, gender, and
history of diabetes mellitus, hypertension, coronary artery disease,
stroke, and chronic heart failure were obtained from medical
records or interviews with patients. Study subjects were deﬁned as
having diabetes mellitus if the fasting blood glucose level was
greater than 126 mg/dL or hypoglycemic agents were used to
control blood glucose levels. Similarly, study patients were
considered as having hypertension if the systolic blood pressure
was 140 mmHg or diastolic blood pressure 90 mmHg or anti-
hypertensive drugs were prescribed. Stroke was deﬁned as a
history of cerebrovascular accident including cerebral bleeding or
infarction. Coronary artery disease was deﬁned as a history
of typical angina with positive stress test, angiographically
Fig. 1. In this representative case, the preceding and pre-preceding intervals of the index beat were 874 and 895 ms. Using tissue Doppler echocardiography, we can measure
pre-ejection period (PEPa), deﬁned as the interval measured from the onset of QRS to the onset of the systolic mitral annular velocity pattern, ejection time (ETa), deﬁned as
the interval measured from the onset to the end of systolic mitral annular velocity pattern, and isovolumic relaxation time (IVRTa), deﬁned as the interval measured from the
end of systolic mitral annular velocity pattern to the onset of diastolic mitral annular velocity pattern on the same cardiac cycle. The PEPa-derived myocardial performance
index was deﬁned as the ratio of PEPa + IVRTa to ETa.
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having undergone coronary artery bypass surgery or angioplasty.
Heart failure was deﬁned according to Framingham criteria.
Laboratory data were also collected. In addition, information
regarding patient medications including angiotensin-converting
enzyme inhibitors, angiotensin II receptor blockers, b-blockers,
calcium channel blockers, diuretics, and antiplatelet and antico-
agulant agents during the study period was obtained from medical
records.
Deﬁnition of CV events
CV events were deﬁned as CV death, nonfatal stroke, and
hospitalization for heart failure. Hospitalization for heart failure
was deﬁned as admission due to dyspnea with chest radiographic
evidence of pulmonary congestion and treatment with intravenous
diuretics. CV events were ascertained and adjudicated by two
cardiologists with disagreement resolved by adjudication from a
third cardiologist from the hospital course and medical record. If
patients had multiple CV events, only the ﬁrst event was coded.
However, patients who died following a stroke or heart failure
hospitalization at the same admission were coded as CV death. In
patients reaching the study end points, they were followed until
the ﬁrst episode of CV events. The other patients were followed
until November 2012.
Statistical analysis
SPSS 18.0 software (SPSS, Chicago, IL, USA) was used for
statistical analysis. Data were expressed as mean  standard
deviation or percentage. Continuous and categorical variables
between groups were compared by independent samples t-test
and Chi-square test, respectively. The signiﬁcant variables in the
univariate analysis were selected for multivariate analysis. Time to
the CV events and covariates of risk factors were modeled using Cox
proportional forward hazards model. The incremental value of PEPa-
derived MPI over conventional parameters to assess the risk for CV
events was studied by calculating the improvement in global Chi-
square. Kaplan–Meier survival plot was calculated from baseline to
time of adverse CV events and compared using the log-rank test. The
stepwise multiple linear regression analysis was employed to identifythe determinants of PEPa-derived MPI. All tests were two-sided and
the level of signiﬁcance was established as p < 0.05.
Results
Table 1 shows the comparison of clinical and echocardiographic
characteristics between patients with and without CV events. The
mean age of all patients was 70  10 years. Compared to patients
without CV events, patients with CV events had an older age, lower
prevalence of hypertension, higher prevalence of chronic heart
failure, lower body mass index, higher percentage of diuretic use,
larger LAVI and left ventricular end diastolic and systolic dimensions,
higher LVMI, lower LVEF, Ea and Sa, higher E/Ea, longer PEPa and
IVRTa, shorter Eta, and higher PEPa-derived MPI.
Table 2 shows the correlates of PEPa-derived MPI in study
patients. After the multivariate analysis, increased heart rate and
LVMI and decreased LVEF, E and Ea were independently associated
with increased PEPa-derived MPI.
The follow-up period was 16.5  8.4 months in all patients and
18.4  8.1 months in patients without CV events (range 5–31
months). Fifty-one CV events were documented during the follow-
up period, including CV death (n = 16), nonfatal stroke (n = 13), and
hospitalization for heart failure (n = 22). A Cox proportional
forward hazards regression analysis for CV events is shown in
Table 3. The univariate regression analysis showed that old age, the
presence of chronic heart failure, low body mass index, diuretic
use, increased LAVI, left ventricular end-diastolic and end-systolic
dimensions, LVMI, E/Ea, PEPa, IVRTa and PEPa-derived MPI, and
decreased LVEF, Ea, Sa, and ETa were signiﬁcantly associated with
an increase in CV events. In the multivariate analysis, the presence
of chronic heart failure and increased E/Ea and PEPa-derived MPI
[per 0.1 increase, hazard ratio (HR), 1.104; 95% conﬁdence interval
(CI), 1.032–1.182, p = 0.004] were independently associated with
increased CV events. In addition, we also performed subgroup
analyses in patients with LVEF 3 50% (n = 136) and LVEF < 50%
(n = 60). In the multivariate analysis, PEPa-derived MPI (per 0.1
increase, HR 1.437; 95% CI 1.087–1.899, p = 0.011) and E/Ea were
independent predictors of CV events in patients with LVEF 3 50%
and the presence of chronic heart failure and increased LAVI were
independent predictors of CV events in patients with LVEF < 50%
(Table 4).
Table 1
Comparison of clinical and echocardiographic characteristics between patients with and without CV events.
Characteristics Patients with CV events (n = 51) Patients without CV events (n = 145) p All patients (n = 196)
Age (years) 73  9 69  10 0.015 70  10
Male gender (%) 71 66 0.495 67
Diabetes mellitus (%) 24 28 0.555 27
Hypertension (%) 51 66 0.047 62
Coronary artery disease (%) 14 9 0.342 10
Stroke (%) 16 18 0.702 17
Chronic heart failure (%) 51 20 <0.001 28
Systolic blood pressure (mmHg) 133  23 132  19 0.827 132  20
Diastolic blood pressure (mmHg) 75  12 77  12 0.426 77  12
Heart rate (min1) 84  20 83  20 0.863 83  20
Body mass index (kg/m2) 24.8  3.4 26.5  4.3 0.013 26.1  4.2
Triglyceride (mg/dL) 123  76 124  81 0.950 123  80
Total cholesterol (mg/dL) 170  35 174  36 0.533 173  36
Medications
ACEI and/or ARB use (%) 55 53 0.860 54
b-Blocker use (%) 45 43 0.800 43
Calcium channel blocker use (%) 31 35 0.601 34
Diuretics use (%) 57 37 0.016 42
Antiplatelet use (%) 51 61 0.227 58
Anticoagulant use (%) 29 30 0.508 30
Echocardiographic data
LAVI (ml/m2) 54  25 46  19 0.023 48  21
LVEDD (mm) 54  10 51  7 0.015 52  8
LVESD (mm) 39  11 35  8 0.002 36  9
LVMI (g/m2) 157  47 131  37 <0.001 138  41
LVEF (%) 49.0  16.9 56.9  12.7 0.001 54.8  14.3
E (cm/s) 100  27 96  21 0.282 97  23
EDT (ms) 158  67 146  35 0.139 149  46
Ea (cm/s) 7.5  2.1 9.3  2.3 <0.001 8.8  2.4
E/Ea 14.1  5.6 10.9  3.7 <0.001 11.8  4.5
Sa (cm/s) 5.45  1.66 6.47  1.38 <0.001 6.20  1.52
PEPa (ms) 103  28 94  22 0.016 96  24
ETa (ms) 235  41 253  33 0.002 248  36
IVRTa (ms) 92  29 74  21 <0.001 79  24
PEPa-derived MPI 0.88  0.36 0.69  0.22 <0.001 0.74  0.28
Follow-up period (month) 10.9  6.6 18.4  8.1 <0.001 16.5  8.4
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CV, cardiovascular events; E, transmitral E-wave velocity; Ea, early diastolic mitral annulus velocity; EDT, E-
wave deceleration time; ETa, ejection time measured from tissue Doppler echocardiography; IVRTa, isovolumic relaxation time measured from tissue Doppler echocardiography; LAVI, left atrial
volume index; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVMI, left ventricular mass index; MPI,
myocardial performance index; PEPa, pre-ejection period measured from tissue Doppler echocardiography; Sa, systolic mitral annulus velocity.
Table 2
Univariate and multivariate correlates of PEPa-derived MPI in study patients.
Univariate analysis Multivariate analysis (stepwise)
Standardized coefﬁcient b p Standardized coefﬁcient b p
Age (years) 0.011 0.878
Male gender 0.047 0.518
Diabetes mellitus 0.081 0.262
Hypertension 0.070 0.334
Coronary artery disease 0.074 0.308
Stroke 0.090 0.210
Chronic heart failure 0.285 <0.001 0.076 0.189
Systolic blood pressure (mmHg) 0.120 0.111
Diastolic blood pressure (mmHg) 0.014 0.850
Heart rate (min1) 0.271 <0.001 0.147 0.007
Body mass index (kg/m2) 0.141 0.056
Triglyceride (mg/dL) 0.085 0.302
Total cholesterol (mg/dL) 0.020 0.806
Medications
ACEI and/or ARB use 0.058 0.425
b-Blocker use 0.029 0.684
Calcium channel blocker use 0.058 0.425
Diuretics use 0.149 0.038 0.018 0.736
Antiplatelet use 0.056 0.436
Anticoagulant use 0.110 0.127
Echocardiographic data
LAVI (ml/m2) 0.081 0.276
LVEDD (mm) 0.388 <0.001 0.019 0.808
LVESD (mm) 0.485 <0.001 0.011 0.893
LVMI (g/m2) 0.399 <0.001 0.142 0.015
LVEF (%) 0.583 <0.001 0.294 <0.001
E (cm/s) 0.312 0.001 0.242 <0.001
EDT (ms) 0.001 0.993
Ea (cm/s) 0.537 <0.001 0.361 <0.001
E/Ea 0.234 0.001 0.216 0.158
Sa (cm/s) 0.478 <0.001 0.047 0.560
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; E, transmitral E-wave velocity; Ea, early diastolic mitral annulus velocity; EDT, E-wave deceleration time;
LAVI, left atrial volume index; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVMI, left ventricular mass
index; MPI, myocardial performance index; PEPa, pre-ejection period measured from tissue Doppler echocardiography; Sa, systolic mitral annulus velocity.
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Table 3
Predictors of cardiovascular events using Cox proportional hazards model.
Parameter Univariate Multivariate (forward)
HR (95% CI) p HR (95% CI) p
Age (per 1 year) 1.038 (1.008–1.069) 0.012
Male versus female 0.856 (0.469–1.564) 0.613
Diabetes mellitus 1.055 (0.551–2.018) 0.872
Hypertension 0.746 (0.428–1.300) 0.299
Coronary artery disease 1.587 (0.714–3.526) 0.253
Stroke 1.194 (0.559–2.550) 0.647
Chronic heart failure 3.029 (1.747–5.250) <0.001 2.700 (1.430–5.099) 0.002
Systolic blood pressure (per 1 mmHg) 1.001 (0.986–1.015) 0.942
Diastolic blood pressure (per 1 mmHg) 0.988 (0.963–1.013) 0.338
Heart rate (per 1 bpm) 1.001 (0.987–1.015) 0.895
Body mass index (per 1 kg/m2) 0.904 (0.837–0.977) 0.012
Triglyceride (per 1 mg/dL) 0.999 (0.995–1.003) 0.696
Cholesterol (per 1 mg/dL) 0.998 (0.989–1.007) 0.653
Medications
ACEI and/or ARB use 1.024 (0.590–1.780) 0.932
b-Blocker use 0.921 (0.530–1.602) 0.770
Calcium channel blocker use 1.067 (0.589–1.932) 0.831
Diuretics use 1.824 (1.048–3.176) 0.031
Antiplatelet use 0.794 (0.458–1.375) 0.409
Anticoagulant use 1.106 (0.605–2.022) 0.744
Echocardiographic data
LAVI (per 1 ml/m2) 1.016 (1.004–1.027) 0.008
LVEDD (per 1 mm) 1.037 (1.000–1.074) 0.048
LVESD (per 1 mm) 1.042 (1.012–1.074) 0.005
LVMI (per 1 g/m2) 1.012 (1.005–1.018) <0.001
LVEF (per 1%) 0.968 (0.950–0.986) <0.001
E (per 1 cm/s) 1.010 (0.998–1.022) 0.108
EDT (per 1 ms) 1.005 (1.000–1.010) 0.067
Ea (per 1 cm/s) 0.748 (0.659–0.849) <0.001
E/Ea (per 1) 1.106 (1.061–1.152) <0.001 1.076 (1.030–1.124) 0.001
Sa (per 1 cm/s) 0.648 (0.526–0.799) <0.001
PEPa (per 1 ms) 1.011 (1.000–1.022) 0.043
ETa (per 1 ms) 0.988 (0.980–0.995) 0.001
IVRTa (per 1 ms) 1.022 (1.013–1.032) <0.001
PEPa-derived MPI (per 0.1) 1.155 (1.084–1.230) <0.001 1.104 (1.032–1.182) 0.004
HR, hazard ratio; CI, conﬁdence interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; E, transmitral E-wave velocity; Ea, early
diastolic mitral annulus velocity; EDT, E-wave deceleration time; ETa, ejection time measured from tissue Doppler echocardiography; IVRTa, isovolumic relaxation time
measured from tissue Doppler echocardiography; LAVI, left atrial volume index; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction;
LVESD, left ventricular end-systolic dimension; LVMI, left ventricular mass index; MPI, myocardial performance index; PEPa, pre-ejection period measured from tissue
Doppler echocardiography; Sa, systolic mitral annulus velocity.
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predictor of the outcome, we created several models using
different cut-off values of PEPa-derived MPI. Using the Chi-square
value to select the model with the best performance, the model
using PEPa-derived MPI 3 0.72 had the best performance in
predicting the adverse CV events. Fig. 2 illustrates the Kaplan–
Meier curve for CV event-free survival in study patients subdivided
according to PEPa-derived MPI < 0.72 or 30.72 (log-rank
p < 0.001). In addition, in Kaplan–Meier analysis, PEPa-derived
MPI 3 0.72 also predicted the combined end points of CV death
and non-fatal stroke (log-rank p = 0.001).
The incremental value of PEPa-derived MPI in outcome
prediction was shown in Fig. 3. The clinical model including
chronic heart failure, systolic blood pressure, age, diabetes, and
prior stroke could signiﬁcantly predict the adverse CV events (Chi-
square = 16.813, p = 0.005). The addition of LVEF to the clinical
model offered an extra beneﬁt in prediction of adverse CV events
(p = 0.007). The addition of E/Ea and the addition of PEPa-derived
MPI to the model including clinical model and LVEF also provided
extra beneﬁts in prediction of adverse CV events (p = 0.021 and
p = 0.008, respectively). However, there was no signiﬁcant differ-
ence in prediction of adverse CV events between the model
including clinic model, LVEF and E/Ea and the model including
clinical model, LVEF and PEPa-derived MPI (p = 0.080). Besides, the
addition of PEPa-derived MPI to the model including clinicalmodel, LVEF, and E/Ea further provided an extra beneﬁt in
prediction of adverse CV events (p = 0.015). In contrast, the
addition of E/Ea to the model including clinical model, LVEF, and
PEPa-derived MPI could not provide an extra beneﬁt in prediction
of adverse CV events (p = 0.093).
The PEPa-derived MPI obtained from index beat method had a
highly signiﬁcant correlation with that obtained from the average
method in 51 study patients (r = 0.929, p < 0.001). Bland–Altman
analysis showed only small bias of 0.04 and the 95% limit of
agreement was +0.14 to 0.22 (Fig. 4).
Discussion
In the present study, we evaluated the association of PEPa-
derived MPI with CV outcomes in patients with AF. We found that
increased PEPa-derived MPI had a signiﬁcant correlation with
echocardiographic left ventricular systolic and diastolic function
and this index was a useful predictor of adverse CV events in all
study patients and in patients with LVEF 3 50% after adjustment
for important clinical and echocardiographic parameters. The
increase in PEPa-derived MPI could also add signiﬁcant incremen-
tal prognostic value for CV events beyond conventional clinical and
echocardiographic parameters. In addition, use of the index beat to
measure PEPa-derived MPI in AF patients was as accurate as the
time-consuming method of averaging multiple cardiac cycles.
Table 4
Predictors of cardiovascular events using Cox proportional hazards model in atrial ﬁbrillation patients with preserved LVEF (350%) and reduced LVEF (<50%).
Preserved LVEF (350%) Reduced LVEF (<50%)
Univariate Multivariate (forward) Univariate Multivariate (forward)
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age (per 1 year) 1.061 (1.015–1.109) 0.008 1.014 (0.976–1.055) 0.475
Male versus female 0.894 (0.395–2.024) 0.788 1.370 (0.545–3.445) 0.503
Diabetes mellitus 1.059 (0.421–2.666) 0.903 1.133 (0.454–2.827) 0.789
Hypertension 1.041 (0.459–2.364) 0.923 0.561 (0.259–1.215) 0.143
Coronary artery disease 1.187 (0.279–5.052) 0.817 1.364 (0.513–3.622) 0.534
Stroke 1.347 (0.458–3.965) 0.588 1.019 (0.350–2.963) 0.972
Chronic heart failure 2.318 (1.024–5.248) 0.044 2.640 (1.169–5.961) 0.019 3.070 (1.221–7.724) 0.017
Systolic blood pressure
(per 1 mmHg)
1.015 (0.995–1.035) 0.154 0.988 (0.967–1.009) 0.257
Diastolic blood pressure
(per 1 mmHg)
1.012 (0.975–1.049) 0.535 0.964 (0.929–1.000) 0.047
Heart rate (per 1 bpm) 1.002 (0.982–1.012) 0.843 0.991 (0.971–1.012) 0.394
Body mass index (per 1 kg/m2) 0.885 (0.793–0.988) 0.029 0.956 (0.855–1.070) 0.435
Triglyceride (per 1 mg/dL) 0.998 (0.991–1.006) 0.677 0.999 (0.994–1.005) 0.835
Cholesterol (per 1 mg/dL) 0.995 (0.981–1.009) 0.479 1.000 (0.987–1.013) 0.981
Medications
ACEI and/or ARB use 0.931 (0.425–2.042) 0.858 0.919 (0.419–2.019) 0.834
b-Blocker use 1.108 (0.504–2.438) 0.798 0.890 (0.403–1.964) 0.773
Calcium channel blocker use 1.317 (0.588–2.951) 0.503 1.263 (0.506–3.155) 0.617
Diuretics use 1.503 (0.685–3.295) 0.309 1.730 (0.770–3.884) 0.184
Antiplatelet use 0.740 (0.338–1.623) 0.453 1.013 (0.467–2.196) 0.974
Anticoagulant use 1.588 (0.700–3.602) 0.268 0.717 (0.287–1.787) 0.475
Echocardiographic data
LAVI (per 1 ml/m2) 1.000 (0.977–1.023) 0.991 1.021 (1.007–1.035) 0.002 1.014 (1.003–1.025) 0.014
LVEDD (per 1 mm) 0.950 (0.889–1.015) 0.127 1.049 (0.996–1.105) 0.069
LVESD (per 1 mm) 0.977 (0.919–1.040) 0.465 1.037 (0.990–1.086) 0.129
LVMI (per 1 g/m2) 1.004 (0.994–1.014) 0.482 1.015 (1.005–1.025) 0.002
LVEF (per 1%) 1.011 (0.955–1.071) 0.704 0.972 (0.929–1.016) 0.209
E (per 1 cm/s) 1.013 (0.996–1.029) 0.130 1.021 (1.002–1.041) 0.033
EDT (per 1 ms) 1.008 (1.002–1.015) 0.015 1.002 (0.994–1.010) 0.639
Ea (per 1 cm/s) 0.707 (0.576–0.869) 0.001 0.869 (0.706–1.070) 0.185
E/Ea (per 1) 1.127 (1.045–1.216) 0.002 1.119 (1.038–1.207) 0.003 1.072 (1.015–1.132) 0.013
Sa (per 1 cm/s) 0.658 (0.472–0.918) 0.014 0.777 (0.528–1.143) 0.200
PEPa (per 1 ms) 1.008 (0.989–1.0283) 0.404 1.001 (0.986–1.016) 0.925
ETa (per 1 ms) 0.988 (0.975–1.001) 0.061 0.994 (0.984–1.005) 0.301
IVRTa (per 1 ms) 1.030 (1.010–1.051) 0.003 1.014 (1.000–1.027) 0.047
PEPa-derived MPI (per 0.1) 1.485 (1.161–1.899) 0.002 1.437 (1.087–1.899) 0.011 1.066 (0.964–1.179) 0.215
HR, hazard ratio; CI, conﬁdence interval; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; E, transmitral E-wave velocity; Ea, early diastolic mitral
annulus velocity; EDT, E-wave deceleration time; ETa, ejection time measured from tissue Doppler echocardiography; IVRTa, isovolumic relaxation time measured from tissue Doppler
echocardiography; LAVI, left atrial volume index; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension;
LVMI, left ventricular mass index; MPI, myocardial performance index; PEPa, pre-ejection period measured from tissue Doppler echocardiography; Sa, systolic mitral annulus velocity.
Fig. 2. Kaplan–Meier analysis of cardiovascular event-free survival according to
pre-ejection period-derived myocardial performance index (PEPa-derived MPI)
<0.72 or 30.72.
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tissue image-derived parameters in major cardiac diseases such as
heart failure [24], acute myocardial infarction [25], and hyperten-
sion. The Ea, E/Ea, and Sa are shown to predict mortality or CV
events in these cardiac diseases. Patients with reduced Ea and Sa
values, in particular, have a poor prognosis [26]. Besides, left
ventricular and left atrial size, left ventricular hypertrophy and left
ventricular systolic function were reported to be able to predict CV
outcomes [27–30]. In this study, although Ea, Sa, left ventricular
dimensions, LAVI, LVMI, and LVEF were associated with increased
CV events in the univariate analysis, the association became
insigniﬁcant after the multivariate analysis. Only E/Ea and PEPa-
derived MPI were still the major determinants of adverse CV
events. Hence, the PEPa-derived MPI, an indicator combining left
ventricular systolic and diastolic function, may be a more useful
prognostic parameter for CV events in patients with AF.
AF patients with preserved ejection fraction are also at high risk
for developing heart failure [3–5]. Therefore, only consideration of
left ventricular systolic function should not be good enough in
accurate prediction of adverse CV events in AF patients. In contrast,
concurrent consideration of left ventricular systolic and diastolic
function should be able to improve CV outcome prediction in AF
patients. In this study, the addition of left ventricular diastolic
parameter, E/Ea, to the clinical model and LVEF actually provided
an additional beneﬁt in prediction of adverse CV events. This result
was consistent with the previous ﬁndings, i.e. additional consid-
eration of left ventricular diastolic function was helpful in
Fig. 3. Addition of pre-ejection period-derived myocardial performance index (PEPa-derived MPI) to a Cox model consisting of clinical model (chronic heart failure, systolic
blood pressure, age, diabetes, prior stroke), left ventricular ejection fraction (LVEF) and the ratio of trasmitral E-wave velocity to early diastolic annulus velocity (E/Ea)
resulted in a signiﬁcant improvement in the predictive value for adverse cardiovascular events.
C.-Y. Chu et al. / Journal of Cardiology 65 (2015) 466–473472improving CV outcome prediction in AF patients [6–8]. Besides, the
addition of the PEPa-derived MPI to the model consisting of clinical
model, LVEF, and E/Ea further added signiﬁcant incremental
prognostic value in our study patients. Hence, the PEPa-derived
MPI deserved to be measured during echocardiographic examina-
tion for additional prognostication in patients with AF.
In clinical practice, the acceptable process for obtaining a
reliable assessment of left ventricular function during AF needs
averaging an arbitrary number of cardiac cycles. This process may
be suboptimal because the averaged value is dependent on a
selected window of cardiac cycles. In addition, it is time-
consuming and not realistic in the clinical scenario to analyze
more than 10 beats for evaluating left ventricular performance.
Prior studies have found that the left ventricular systolic and atrial
parameters measured from index beat are reasonable estimates of
the measured average values over all cardiac cycles [20–22]. In the
present study, we also demonstrated that using the index beat to
measure PEPa-derived MPI was as accurate as and less time-
consuming than the onerous method of averaging of multiple
cardiac cycles. In addition, our recent study showed that theFig. 4. Bland–Altman plot of pre-ejection period-derived myocardial performance
index measured from the index beat method (PEPa-derived MPIib) and average
method (PEPa-derived MPIavg) in 51 study subjects.PEPa-derived MPI measured from average method was signiﬁ-
cantly associated with left ventricular systolic and diastolic
function [17]. The present study demonstrated that PEPa-derived
MPI measured by index beat method also had a signiﬁcant
correlation with LVEF and Ea. Hence, the PEPa-derived MPI
measured from index beat was an easily obtained and less time-
consuming parameter in evaluation of global left ventricular
function and could be used to predict CV outcomes in AF patients.
Study limitations
There were several limitations to this study. Because their
measurements using average method were time-consuming, many
echocardiographic parameters including left ventricular dimen-
sions, LVEF, LAVI, LVMI, PEPa, ETa, IVRTa, and PEPa-derived MPI
were not obtained from the averaging multiple cardiac cycles, but
measured from the index beat. However, several studies including
the present one had proven use of the index beat to measure
certain echocardiographic parameters including left ventricular
systolic, diastolic, and left atrial parameters in patients with AF
was as accurate as the time-consuming method of averaging
multiple cardiac cycles [20–22]. The majority of our patients were
treated chronically with antihypertensive or anti-thrombosis
medications. For ethical reasons, we did not withdraw these
agents. Hence, we could not exclude the inﬂuence of these agents
on the present ﬁndings. However, we have adjusted the use of
medicine in the multivariate analysis. Because there was no study
to establish a reliable and optimal upper limit value for the
difference between the preceding and pre-preceding intervals of
the index beat, as with previous studies [20,22], we arbitrarily
chose 60 ms as the cut-off value for this difference. The rate of
anticoagulation therapy was low in our study but it was similar to
our national survey for AF [31]. The CV event rate in this study was
relatively high (26%), which might be partially explained by the
low rate of anticoagulation therapy. In addition, since the subjects
of this study were already being evaluated for heart disease by
echocardiography, it was susceptible to selection bias and making
ﬁndings potentially less generalized.
Conclusions
Our study in AF patients demonstrated that the PEPa-derived
MPI was independently associated with an increase in adverse CV
C.-Y. Chu et al. / Journal of Cardiology 65 (2015) 466–473 473events and could add signiﬁcant incremental prognostic value
beyond conventional clinical and echocardiographic parameters.
Hence, this index deserved to be measured during echocardio-
graphic examination for additional prognostication in patients
with AF.
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